Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.

Claus-Henning KöhneMeinolf KarthausLaurent MineurJosef ThalerMarc Van den EyndeJavier Gallego PlazasReija KoukakisMarloes BerkhoutRalf-Dieter Hofheinz

Published in: Drugs in R&D (2020)

NCT00508404.

Keyphrases

wild type
metastatic colorectal cancer
type diabetes
metabolic syndrome
adipose tissue
weight loss
insulin resistance